Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could spare colon cancer patients from unnecessary chemo

NCT ID NCT06111105

Knowledge-focused Sponsor: Claus Lindbjerg Andersen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a simple blood test can find tiny bits of cancer DNA left after surgery for stage III colorectal cancer. The goal is to see if this test can help doctors decide who really needs extra chemotherapy and who can skip it. About 590 people will give blood samples at different times to compare different test methods. The study does not offer a new treatment but aims to improve how we personalize cancer care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 590 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2023

Expected to finish

Jul 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Colorectal cancer stage III: patient with stage III colorectal cancer treated with curative-intent surgery and adjuvant chemotherapy Colorectal cancer liver metastasis: patient with colorectal cancer liver metastasis

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Colorectal cancer stage III Inclusion Criteria: * Colorectal cancer, UICC stage III * Has received curative-intent resection and is a candidate for adjuvant chemotherapy * Patient able to understand and sign written informed consent Exclusion Criteria: * Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome * Inflammatory bowel disease (Crohn's disease or ulcerative colitis) * Verified distant metastases * Not treated with adjuvant chemotherapy despite indication (incomplete treatment not included) * Treated with neoadjuvant chemo-radiation therapy * No tissue sample available for the project, or tumor content in the tissue sample is \<20% * Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma) * Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening * Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study Colorectal cancer liver metastasis Inclusion Criteria: * Colorectal cancer liver metastasis * Planned for curative-intent treatment * Performance status 0-1 Exclusion Criteria: * Liver cirrhosis * Extrahepatic metastases * Other cancer within the last 5 years * Intervention not performed with curative intent * No tissue available from CRLM or primary tumor

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer stage III are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma colorectal neoplasm metastasis from malignant tumor of colon Neoplasm, Residual

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer stage III Liver metastasis colon cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aalborg University Hospital

    RECRUITING

    Aalborg, North Denmark, 9000, Denmark

  • Aarhus University Hospital

    RECRUITING

    Aarhus, Central Jutland, 8000, Denmark

  • Abteilung für Onkologie, Medizinische Universität Graz

    RECRUITING

    Graz, Styria, 8010, Austria

  • Bispebjerg Hospital

    RECRUITING

    Copenhagen, Capital Region of Denmark, 2400, Denmark

  • Department of General-, Visceral- and Thoracic Surgery, University Medical Center Hamburg-Eppendorf

    RECRUITING

    Hamburg, Free and Hanseatic City of Hamburg, 20246, Germany

  • Gødstrup Hospital

    RECRUITING

    Herning, Central Jutland, 7400, Denmark

  • Herlev Hospital

    NOT_YET_RECRUITING

    Herlev, Capital Region of Denmark, 2730, Denmark

  • Karolinska University Hospital

    RECRUITING

    Huddinge, Stockholm County, 14183, Sweden

  • LCCRH (Laboratoire Cellules Circulantes Rares Humaines) - CHU de Montpellier

    RECRUITING

    Montpellier, 34295, France

  • Odense University Hospital

    RECRUITING

    Odense, The Region of Southern Denmark, 5000, Denmark

  • Ordenskrankenhaus Graz Mitte

    RECRUITING

    Graz, Styria, 8010, Austria

  • Regional Hospital Horsens

    RECRUITING

    Horsens, Central Jutland, 8700, Denmark

  • Regional Hospital Randers

    RECRUITING

    Randers, Central Jutland, 8930, Denmark

  • Regional Hospital Viborg

    RECRUITING

    Viborg, Central Jutland, 8800, Denmark

  • Universitätsklinikum Hamburg-Eppendorf

    RECRUITING

    Hamburg, Free and Hanseatic City of Hamburg, 20246, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.